T1	Participants 108 146	patients with advanced cervical cancer
T2	Participants 385 472	31 women with FIGO stage IB2-IVA cervical cancer or with postsurgical pelvic recurrence
T3	Participants 1052 1116	Seven patients (44%) of group I and 8 patients (53%) of group II
T4	Participants 1244 1349	patients surviving at 2 and 5 years was 78% and 54% for group I and 73% and 43% for group II respectively
